Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

159 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Could Children's Myopization Have Been Avoided during the Pandemic Confinement? The Conjunctival Ultraviolet Autofluorescence (CUVAF) Biomarker as an Answer.
de la Puente M, Irigoyen-Bañegil C, Ortega Claici A, González-Zamora J, Bilbao-Malavé V, Fernandez-Robredo P, Hernández M, Barrio J, García-Layana A, Recalde S. de la Puente M, et al. Among authors: garcia layana a. Biomedicines. 2024 Feb 1;12(2):347. doi: 10.3390/biomedicines12020347. Biomedicines. 2024. PMID: 38397949 Free PMC article.
Legume consumption is inversely associated with type 2 diabetes incidence in adults: A prospective assessment from the PREDIMED study.
Becerra-Tomás N, Díaz-López A, Rosique-Esteban N, Ros E, Buil-Cosiales P, Corella D, Estruch R, Fitó M, Serra-Majem L, Arós F, Lamuela-Raventós RM, Fiol M, Santos-Lozano JM, Díez-Espino J, Portoles O, Salas-Salvadó J; PREDIMED Study Investigators. Becerra-Tomás N, et al. Clin Nutr. 2018 Jun;37(3):906-913. doi: 10.1016/j.clnu.2017.03.015. Epub 2017 Mar 24. Clin Nutr. 2018. PMID: 28392166
Effect of a Lifestyle Intervention Program With Energy-Restricted Mediterranean Diet and Exercise on Weight Loss and Cardiovascular Risk Factors: One-Year Results of the PREDIMED-Plus Trial.
Salas-Salvadó J, Díaz-López A, Ruiz-Canela M, Basora J, Fitó M, Corella D, Serra-Majem L, Wärnberg J, Romaguera D, Estruch R, Vidal J, Martínez JA, Arós F, Vázquez C, Ros E, Vioque J, López-Miranda J, Bueno-Cavanillas A, Tur JA, Tinahones FJ, Martín V, Lapetra J, Pintó X, Daimiel L, Delgado-Rodríguez M, Matía P, Gómez-Gracia E, Díez-Espino J, Babio N, Castañer O, Sorlí JV, Fiol M, Zulet MÁ, Bulló M, Goday A, Martínez-González MÁ; PREDIMED-Plus investigators. Salas-Salvadó J, et al. Diabetes Care. 2019 May;42(5):777-788. doi: 10.2337/dc18-0836. Epub 2018 Nov 2. Diabetes Care. 2019. PMID: 30389673 Free article. Clinical Trial.
Mediterranean Diet, Retinopathy, Nephropathy, and Microvascular Diabetes Complications: A Post Hoc Analysis of a Randomized Trial.
Díaz-López A, Babio N, Martínez-González MA, Corella D, Amor AJ, Fitó M, Estruch R, Arós F, Gómez-Gracia E, Fiol M, Lapetra J, Serra-Majem L, Basora J, Basterra-Gortari FJ, Zanon-Moreno V, Muñoz MÁ, Salas-Salvadó J; PREDIMED Study Investigators. Díaz-López A, et al. Diabetes Care. 2015 Nov;38(11):2134-41. doi: 10.2337/dc15-1117. Epub 2015 Sep 13. Diabetes Care. 2015. PMID: 26370380 Clinical Trial.
TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2.
Khanani AM, Kotecha A, Chang A, Chen SJ, Chen Y, Guymer R, Heier JS, Holz FG, Iida T, Ives JA, Lim JI, Lin H, Michels S, Quezada Ruiz C, Schmidt-Erfurth U, Silverman D, Singh R, Swaminathan B, Willis JR, Tadayoni R; TENAYA and LUCERNE Investigators. Khanani AM, et al. Ophthalmology. 2024 Feb 19:S0161-6420(24)00134-9. doi: 10.1016/j.ophtha.2024.02.014. Online ahead of print. Ophthalmology. 2024. PMID: 38382813 Free article.
Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.
Wong TY, Haskova Z, Asik K, Baumal CR, Csaky KG, Eter N, Ives JA, Jaffe GJ, Korobelnik JF, Lin H, Murata T, Ruamviboonsuk P, Schlottmann PG, Seres AI, Silverman D, Sun X, Tang Y, Wells JA, Yoon YH, Wykoff CC; YOSEMITE and RHINE Investigators. Wong TY, et al. Ophthalmology. 2024 Jun;131(6):708-723. doi: 10.1016/j.ophtha.2023.12.026. Epub 2023 Dec 28. Ophthalmology. 2024. PMID: 38158159 Free article. Clinical Trial.
Macular Neovascularization Type Influence on Anti-VEGF Intravitreal Therapy Outcomes in Age-Related Macular Degeneration.
Izquierdo-Serra J, Martin-Pinardel R, Moll-Udina A, Bernal-Morales C, Garay-Aramburu G, Sanchez-Monroy J, Arruabarrena C, Fernandez-Hortelano A, Figueroa MS, Abraldes M, Lavid de Los Mozos FJ, Zapata MA, Ruiz-Moreno JM, Broc-Iturralde L, Gonzalez-Guijarro J, Escobar-Barranco JJ, Gallego-Pinazo R, Parrado-Carrillo A, Dotti-Boada M, Alforja S, Figueras-Roca M, Barthelmes D, Gillies MC, Casaroli-Marano RP, Zarranz-Ventura J; Writing Committee of the Fight Retinal Blindness Spain (FRB! Spain) Users Group. Izquierdo-Serra J, et al. Ophthalmol Retina. 2024 Apr;8(4):350-359. doi: 10.1016/j.oret.2023.10.022. Epub 2023 Nov 2. Ophthalmol Retina. 2024. PMID: 37924946
Cost-utility model of new intravitreous units vs. current patient journey model in Spain.
Martín-Saborido C, Zarranz-Ventura J, Escobar-Barranco JJ, Garay-Aramburu G, García-Layana A, Donate-López J, Blanch C, Abraldes M; UTI group. Martín-Saborido C, et al. Among authors: garcia layana a. Arch Soc Esp Oftalmol (Engl Ed). 2023 Nov;98(11):619-626. doi: 10.1016/j.oftale.2023.08.009. Epub 2023 Sep 16. Arch Soc Esp Oftalmol (Engl Ed). 2023. PMID: 37722561
159 results